Open AccessThe Use of Ketamine as Therapy for Depression
Author(s) -
Lovina Lovina
Publication year - 2021
Publication title -
open access indonesian journal of medical reviews
Language(s) - English
Resource type - Journals
ISSN - 2807-6257
DOI - 10.37275/oaijmr.v1i2.34
Subject(s) - ketamine , monoaminergic , depression (economics) , antidepressant , medicine , anesthesia , hypersalivation , sedation , psychology , psychiatry , serotonin , anxiety , receptor , economics , macroeconomics
Depressive disorder is still a significant problem in several developed countriesand is morbidity caused by mental disorders. With the development of science,now discovered the unique pharmacodynamic properties of ketamine, which isused as an antidepressant. As we know in clinical practice, ketamine is used foranaesthesia, analgesia, sedation, and chronic pain management. Rapid-onsetantidepressants resulted from increased levels of BDNF in the hippocampus.Extracellular glutamate agents are not new for the treatment of depression.According to the neurobiology view, depression is a monoaminergic phenomenon,so this is the impetus for discovering a new generation of antidepressants.Ketamine can be given intravenously in subanesthetic doses. Still, monitoringmust be carrying in therapy administration because of the possible side effectssuch as hypersalivation, tachycardia, increased systemic arterial pressure, andintracranial pressure.